Apogee Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2022-01-01
- Employees
- 91
- Market Cap
- $2.6B
- Introduction
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.
A Study Evaluating APG777 in Atopic Dermatitis
Phase 2
Recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: APG777Drug: Placebo
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Apogee Therapeutics, Inc.
- Target Recruit Count
- 391
- Registration Number
- NCT06395948
- Locations
- 🇺🇸
Investigational Site # 46, Los Angeles, California, United States
🇺🇸Investigational Site # 44, New Haven, Connecticut, United States
🇵🇱Investigational Site # 45, Łódź, Łódzkie, Poland
© Copyright 2025. All Rights Reserved by MedPath